Millions may be suffering from a little-known condition that could be hiding behind common symptoms like heartburn, headaches ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated ...

MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

However, there may still be a suspicion for a clonal mast cell disorder, although it may not be as strong ... by which time your patient’s symptoms have typically resolved. This makes tryptase a ...

Sanofi S.A. (Paris, France) and Blueprint Medicines Corp. (Blueprint), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi and Blueprint Medicines Corporation have entered into an agreement under which Sanofi plans to acquire the US biopharmaceutical company Blueprint for 9.1 billion dollars.